Vital Therapies (United States)

Recent papers from Vital Therapies (United States)

1. 68 LNK001 is a High-Fidelity AND-Logic-Gated CAR T Cell Therapy that Enables Precision Targeting of Clear Cell Renal Cell Carcinoma (ccRCC): Target Discovery and Validation for the ATHENA Phase 1 TrialThe Oncologist · 2026
2. 83 Preclinical Evaluation of LNK001: Stringent AND-Gate Fidelity and Potent Efficacy of a Dual-Antigen CAIX/ENPP3 CAR T Cell Therapy for Clear Cell Renal Cell CarcinomaThe Oncologist · 2026
3. Safety and Efficacy of Psilocybin During Anticancer Treatment: A Phase II Trial Secondary AnalysisJournal of Pain and Symptom Management · 2026
4. Eye-tracking working memory intervention in young people with severe dyskinetic cerebral palsy: a pilot studyDisability and Rehabilitation Assistive Technology · 2026
5. The Encounter of Systemic Therapies with Constructionism: A Story yet to Be Explored?Journal of Constructivist Psychology · 2026
6. Correction: Developmental outcome of electroencephalographic findings in SYNGAP1 encephalopathyFrontiers in Cell and Developmental Biology · 2026
7. Association between anxious depression and clinical outcomes in subjects with treatment-resistant depression: a comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD)International Clinical Psychopharmacology · 2026
8. Precision Antisense Oligonucleotide Therapy Amenability for Infantile Genetic EpilepsiesJAMA Neurology · 2026
9. Choosing a biomanufacturing service organization: from the BSO perspectiveCell and Gene Therapy Insights · 2026
10. Awareness and best practices in using ketogenic therapy to treat serious mental illness: a modified Delphi consensusSHILAP Revista de lepidopterología · 2026
11. Editorial: The role of epithelial-derived cytokines in airway diseaseFrontiers in Allergy · 2026
12. Decellularized Dermis ECM-Based Melanoma-on-a-Chip Model with Integrated Lymphatic and Vascular Networks for High-Throughput Drug TestingACS Applied Bio Materials · 2026
13. Patient treatment preference as a predictor of clinical outcomes in subjects with treatment-resistant depression: a comparative effectiveness research trial for antidepressant incomplete and nonresponders with treatment-resistant depression (ASCERTAIN-TRD)International Clinical Psychopharmacology · 2025
14. Understanding racially minoritised clients’ experiences of NHS Talking Therapies: a service evaluation exploring the perspectives of clients most likely to drop out of treatmentThe Cognitive Behaviour Therapist · 2026
15. Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatmentEClinicalMedicine · 2025
16. 4-Methylumbelliferone Modulates CAIX to Mitigate Hypoxia-Driven Dysregulation and Enhance PD-1 Immunotherapy in Lung CancerInternational Journal of Molecular Sciences · 2025
17. Altered Abundance of Barrier-Related Proteins in Brain Microvascular Endothelial Cells of the GL261 Mouse Model of GlioblastomaMolecular Pharmaceutics · 2025
18. Gene therapy for children with X-linked myotubular myopathy: a plain language summary of publication for the ASPIRO studyTherapeutic Advances in Rare Disease · 2025
19. Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trialJournal of Psychopharmacology · 2025
20. Awareness, Knowledge and Perceptions of Pulmonary Rehabilitation Among South Asian Communities in Chronic Respiratory Disease Management: A Cross-Sectional Survey.2025